Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Logo for

J. Pharmacol. Exp. Ther. 324 (1): 34-42

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.

CARDIOVASCULAR

Angiotensin II Activates Extracellular Signal-Regulated Kinase Independently of Receptor Tyrosine Kinases in Renal Smooth Muscle Cells: Implications for Blood Pressure Regulation

Crisanto S. Escano, Jr., Lindsay B. Keever, Alexander A. Gutweiler, and Bradley T. Andresen

Department of Pediatrics, Georgetown University Medical Center, Washington, DC (C.S.E., L.B.K.); and Department of Internal Medicine, Division of Endocrinology, University of Missouri-Columbia School of Medicine, Columbia, Missouri (A.A.G., B.T.A.)

Abstract: Angiotensin II can cause hypertension through enhanced vasoconstriction of renal vasculature. One proposed mechanism for reduction of angiotensin II-induced hypertension is through inhibition of the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase cascade. MEK/ERK has been shown to phosphorylate the regulatory subunit of myosin light chain at identical positions as myosin light chain kinase. There are multiple mechanisms proposed regarding angiotensin II-mediated ERK activation. We hypothesized that renal microvascular smooth muscle cells (RµVSMCs) signal through a unique pathway compared with thoracic aorta smooth muscle cells (TASMCs), which is involved in blood pressure regulation. Use of epidermal growth factor (EGF) and platelet derived growth factor (PDGF) receptor-specific inhibitors 4-(3-chloroanilino)-6,7-dimethoxyquinazoline (AG1478) and 6,7-dimethoxy-3-phenylquinoxaline (AG1296), respectively, demonstrates that angiotensin II activates ERK in TASMCs, but not RµVSMCs, through transactivation of EGF and PDGF receptors. In addition, inhibition of Src with its specific inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) abolishes angiotensin II-, but not EGF-or PDGF-, mediated phosphorylation of ERK in RµVSMCs, yet it has no effect in TASMCs. The physiological significance of transactivation was examined in vivo using anesthetized Wistar-Kyoto rats with 15 mg/kg 2'-amino-3'-methoxyflavone (PD98059), an MEK inhibitor, as well as 20 mg/kg AG1478 and 1.5 mg/kg AG1296 in an acute model of angiotensin II-mediated increase in blood pressure. None of the inhibitors had an effect on basal blood pressure, and only PD98059 reduced angiotensin II-mediated increase in blood pressure. Moreover, in RµVSMCs, but not TASMCs, angiotensin II localizes phosphorylated ERK to actin filaments. In conclusion, angiotensin II signals through a unique mechanism in the renal vascular bed that may contribute to hypertension.


Received for publication May 25, 2007. Accepted for publication October 1, 2007.

Address correspondence to: Dr. Bradley T. Andresen, Internal Medicine/Endocrinology, D109 HSC Diabetes Center, One Hospital Dr., Columbia, MO 65212. E-mail: andresenb{at}health.missouri.edu

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Epidermal growth factors in the kidney and relationship to hypertension.
A. Staruschenko, O. Palygin, D. V. Ilatovskaya, and T. S. Pavlov (2013)
Am J Physiol Renal Physiol 305, F12-F20
   Abstract »    Full Text »    PDF »
Long Range Effect of Mutations on Specific Conformational Changes in the Extracellular Loop 2 of Angiotensin II Type 1 Receptor.
H. Unal, R. Jagannathan, A. Bhatnagar, K. Tirupula, R. Desnoyer, and S. S. Karnik (2013)
J. Biol. Chem. 288, 540-551
   Abstract »    Full Text »    PDF »
The renin-angiotensin system in the breast and breast cancer.
G. P. Vinson, S. Barker, and J. R. Puddefoot (2012)
Endocr. Relat. Cancer 19, R1-R19
   Abstract »    Full Text »    PDF »
Nilotinib Attenuates Renal Injury and Prolongs Survival in Chronic Kidney Disease.
M. Iyoda, T. Shibata, Y. Hirai, Y. Kuno, and T. Akizawa (2011)
J. Am. Soc. Nephrol. 22, 1486-1496
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882